secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106544
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China
--------------------------------------------------------------------------------

- Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.
- Net loss Q2 2025: $7.9M ($2.07 per share) vs $9.6M ($5.52) in Q2 2024.
- R&D expense Q2 2025: $3.9M, down from $5.8M due to re-prioritization toward strategic alternatives.
- Received clearance to start pivotal trial of amezalpat combo for first-line HCC in China; EMA orphan drug designation granted.
- Completed $4.6M registered direct offering in June 2025; net proceeds $4.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017025106544/0000950170-25-106544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017025106544/tpst-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer